News | November 10, 2025
Marksans Pharma's Goa unit clears FDA inspection
The said inspection concluded with Zero Form 483 observation
The said inspection concluded with Zero Form 483 observation
The inspection concluded with zero form 483 observations
The U.S. FDA issued a Form 483 with five observations
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
The inspection concluded with zero Form 483 observations
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
